Latest Breaking News On - China biologic products - Page 4 : comparemela.com

Share this article Share this article ResearchAndMarkets.com s offering. With the adjustment in the catalog of medicines covered by national medical insurance system, the scope and reimbursement ratio of almost all blood products for clinical use grow tremendously, which has further opened up the blood product market. In 2020, the lot release volume of blood products in China sustained growth, hitting 101.31 million bottles, a year-on-year upsurge of 12.7%. Wherein, the lot release volume of human albumin rose 14.78% on an annualized basis, making up 60%; that of human immunoglobulin (pH4) for intravenous injection as a percentage of 12.92% in the total showed a year-on-year increase of 11.78%; that of human tetanus immunoglobulin soared by 76.7% and accounted for 6.9%; other products like human fibrinogen, human prothrombin complex and human coagulation factor VIII took relatively low shares.

Jiangxi boya bioGuangdong shuanglin bioShuanglin bioLaura woodWuhan zhongyuanruide biological products co ltdHealth commission of yunnan provinceHualan biological engineering co ltdMajor enterprisesBohui innovation technologyBlood products co ltdXian huitian blood products co ltdShandong taibang biological products co ltdSichuan yuanda shuyang pharmaceutical co ltdOffice hours callEnterprises make more inputShanxi kangbao biological product co ltd